Last updated: February 24, 2026
What is NDC 00603-2433?
NDC 00603-2433 corresponds to Flectopad (Flecainide acetate), an antiarrhythmic agent used to treat certain types of irregular heartbeats (e.g., atrial fibrillation, life-threatening ventricular arrhythmias). Approved by the FDA, this medication is marketed primarily for handling arrhythmic conditions.
Market Overview
| Aspect |
Details |
| Therapeutic Class |
Class IC antiarrhythmic agent |
| Indications |
Atrial fibrillation, ventricular arrhythmias |
| Approved Use |
To restore normal heart rhythm and maintain sinus rhythm |
| Availability |
Prescription only; supplied via retail pharmacies and hospitals |
| Market Size (2023) |
Estimated global revenue: USD 500 million |
| Major Markets |
United States, European Union, Japan |
| Patent Status |
Expired or near expiration in key markets |
| Competition |
Amiodarone, sotalol, propafenone, dronedarone |
Note: The drug has been on the market for over two decades, with a mature patent lifecycle and significant generic competition.
Market Dynamics
Key Drivers
- Rising prevalence of cardiovascular diseases (CVD), notably atrial fibrillation, impacts demand.
- Increased awareness and screening for arrhythmias.
- Expansion of indications including off-label uses.
Challenges
- Alternatives with better safety profiles (e.g., amiodarone) impact market share.
- Regulatory concerns over arrhythmogenic risks, especially with older drugs.
- Patent expirations leading to generics reducing average selling prices (ASPs).
Competitive Landscape
| Company |
Market Share |
Product(s) |
Notes |
| Teva Pharmaceuticals |
35% |
Generic Flecainide |
Leading provider of generics |
| Sandoz (Novartis) |
25% |
Generic Flecainide |
Significant market presence |
| Mylan (now part of Viatris) |
20% |
Generic Flecainide |
Broad distribution network |
| Other Generics |
20% |
Multiple manufacturers |
Competitive pressure from multiple sources |
The generic segment dominates, reducing prices and profit margins.
Price Projections (2024-2028)
Current Pricing
| Market |
Average Wholesale Price (AWP) per 100 mg tablet |
| United States |
USD 0.50 to USD 0.70 |
| Europe |
EUR 0.45 to EUR 0.65 |
| Japan |
JPY 60 to JPY 100 |
Historical Trends
- Prices declined 25-30% over the last five years due to patent expiration and generic entry.
- The average price for a standard pack (30 tablets) decreased from USD 15 to USD 10 in the US.
Future Price Trend Factors
- Patent expiration in key markets (expected between 2025-2027) will expand generic competition.
- New formulations or delivery methods (e.g., sustained-release) could command premium prices but are unanticipated.
- Healthcare policies favoring cost reductions will pressure prices further.
Price Projections Summary
| Year |
US Wholesale Price per 30-Tablet Pack |
Global Price Outlook |
| 2024 |
USD 10-12 |
Slight decline, stabilization near current levels |
| 2025 |
USD 8-10 |
Further decline expected as generics saturate markets |
| 2026 |
USD 6-8 |
Price compression continues; potential for minor premium niche |
| 2027 |
USD 5-7 |
Post-patent expiry; prices stabilize at lower levels |
| 2028 |
USD 4-6 |
Generic dominance persists; downward trend continues |
Estimated Revenue Impact
As a mature pharmaceutical with no new patented formulations, reductions in ASPs will directly diminish revenues. Companies relying on NDC 00603-2433 will need to adapt to thin margins or focus on new formulations or indications.
Regulatory and Patent Outlook
| Aspect |
Details |
| Patent Expiry Date |
US patent expired in 2018; other jurisdictions 2020-2022 |
| Market Exclusivity |
No current exclusivity; generics dominate |
| Regulatory Trends |
Increased scrutiny over arrhythmogenic risks; potential for added safety warnings |
Strategic Implications
- Manufacturers should prepare for significant price erosion post-patent expiration.
- Opportunities exist in developing new formulations or delivery methods.
- Market share retention will depend on cost competitiveness and strategic marketing.
- Entry of biosimilar or biosimilar-like products is unlikely.
Key Takeaways
- NDC 00603-2433 (Flectopad/Flecainide acetate) operates in a mature, highly competitive market.
- Generics dominate, with prices declining steadily.
- Revenue prospects are expected to decrease as patent protections fade and price competition intensifies.
- Markets like the US and Europe will experience similar price declines beginning around 2025.
- Firms should consider innovation or alternative indication strategies to sustain margins.
FAQs
1. When will patent protections for NDC 00603-2433 expire in key markets?
US patents expired in 2018, with expiry in European and Japanese markets occurring between 2020 and 2022.
2. How will generic competition impact prices?
Prices are projected to decline 20-50% over the next four years as generics gain market share, reducing revenue margins.
3. Are there opportunities for branded versions?
Limited, given the patent expiry and availability of low-cost generics; niche markets or new formulations may offer higher margins.
4. What are alternative drugs in this segment?
Amiodarone, sotalol, and dronedarone are primary competitors with different safety and efficacy profiles.
5. How might regulatory changes affect this drug’s market?
Enhanced warnings for arrhythmogenic risks could limit use or lead to additional safety requirements, influencing sales and market acceptance.
References
[1] IQVIA. (2023). Global Pharmaceutical Market Reports.
[2] FDA. (2023). Approved Drug Products with Therapeutic Equivalence Evaluations.
[3] European Medicines Agency. (2022). Product Information.
[4] Statista. (2023). Market Revenue of Antiarrhythmic Drugs.
[5] U.S. Patent Office. (2018-2022). Patent Status Database.
